Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Bre...( MARSEILLE France July 10 /- Ipsog...),Health

MARSEILLE, France, July 10 /PRNewswire-FirstCall/ -- Ipsogen SA (Alternext: ALIPS) today reported that the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer indicated for the first time that the Genomic Grade could be considered as an adjunct to the histological grade. These new guidelines, published online in Annals of Oncology, represent the consensus opinion of 43 European and US experts on early breast cancer treatment that emerged from the conference which took place in March 2009.

According to the guidelines, histological grade 2 is considered as "not useful for chemo-endocrine-therapy decision" as compared to the established decision making value of histological grades 1 or 3. The panel also stated that the dominant prognostic information is provided by proliferation.

MapQuantTM Genomic Grade is available to European oncologists and pathologists. The genomic grade test analyzes a set of 97 genes to precisely quantify the proliferation potential of the tumor, and has been validated in several studies, covering more than 2 800 tumor samples. MapQuantTM Genomic Grade contributes to high-quality phenotyping of breast cancer, by resolving 80% of histological grade 2 tumors in genomic grade 1 or 3 of similar long term outcome as histological grades 1 and 3.

"The St Gallen Consensus Panel decision to identify the genomic grade as a valuable adjunct in the pathological characterisation of breast cancer legitimates Ipsogen strategy to provide pathologists and oncologists with state of the art molecular tests generating critical information for treatment decisions" said Helene Peyro-Saint-Paul, Chief Medical Officer, Ipsogen. "These new recommendations are going to support our regulatory and reimbursement efforts, a critical step to make our assay widely available to patients and pathologists/physicians," added Vincent Fert, Chief Executive Officer, Ipsogen
'/>"/>